Skip to main content

Fresenius delivers an excellent quarter and is scaling its Growth Vectors - Core EPS guidance improved

In Q3/26, Fresenius continued to build on the structural improvements from its #FutureFresenius transformation, delivering healthy organic revenue growth, double-digit Core EPS growth while further improving returns. The company’s Growth Vectors continued to gain share, while the hospital business sustained resilient growth. Based on the upgraded core and the increased strategic flexibility, Fresenius started to scale its Biopharma business through targeted investments.

 

  • Group revenue1 at €5,803 million with organic growth of 5%1,2 driven by both Fresenius Kabi and Fresenius Helios.  
  • Group EBIT1 at €638 million with 10% growth in constant currency driven by Fresenius Kabi’s Growth Vectors, and Fresenius Helios’ excellent EBIT growth despite the usual seasonality in the hospital business; Group EBIT margin1 expansion by 50 bps to 11.0%. 
  • Core EPS1,3 growth at 14% in constant currency to €0.72 largely driven by strong operating performance and further reduction of interest expense, reflecting the benefits of continued debt reduction. 
  • Group FY/26 guidance on Core EPS growth improved: now expected at the upper half of the 10% to 15% range in constant currency. 
  • Group EBIT margin indication raised: now expected above 11.5% (before around 11.5%) 
  • ROIC at 7.0%, moving up within the Fresenius Financial Framework ambition range of 6% to 8% reaching its highest level of the decade. 
  • Net debt/EBITDA ratio at 2.5x1,4, including about 20bps impact related to mAbxience transaction.

 

1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Excluding Fresenius Medical Care and Vitrea
4 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including dividends from Fresenius Medical Care and Vitrea, net debt adjusted for the valuation effect of the exchangeable bond

 

Selected Key Figures Q3/2026

GROUP REVENUE 1

€ 5803 m

+5% 2

Q3/25: €5,477 m

GROUP EBIT 1

€ 638 m

+10% 4

Q3/25: €574 m

CORE NET INCOME 1, 3

€ 403 m

+14% 4

Q3/25: €351 m

CORE EPS 1, 3

€ 0.72

+14% 4

Q3/25: €0.62

1 Before special items

2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

3 Excluding Fresenius Medical Care and Vitrea

4 Constant currency growth

Revenue by business segment

€ in millions Q3/26 Q3/25 Growth at actual ratesGrowth at constant rates1Organic growth1Acquisitions/Divestitures% of total revenue

Fresenius Kabi

2,3042,1418%5%6%-1%40%

Fresenius Helios

3,4053,2405%4%5%-1%59%

Total

5,8035,4776%4%5%-1%100%2

  • 1 Growth rate adjusted for accounting effects related to Argentina hyperinflation

    2 Remaining 2% Corporate/Other revenue

    Before special items

Archive